Markets

ARIAD (ARIA) Q1 Loss a Penny Wider than Expected - Tale of the Tape

RIAD Pharmaceuticals Inc. ( ARIA ) is a Cambridge, MA-based company, focused on the discovery, development and commercialization of breakthrough treatments for cancer. ARIAD's only approved product is Iclusig (T315I-positive chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia) and the company depends highly on the drug for its growth. ARIAD's revenues consist of product revenues from Iclusig sales and license revenues.

ARIAD is working on studying Iclusig in earlier lines of therapy and intends to initiate three studies in 2015. In this scenario, investor focus remains on the upcoming studies on Iclusig, apart from the usual top-and bottom-line numbers.

ARIAD's performance has been encouraging in 2014 with the company reporting a narrower-than-expected loss in three of the last four trailing quarters with an average beat of 22.38%. Estimates are, however, flat for 2015.

Currently, ARIAD has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: ARIAD reported a first-quarter 2015 loss of 28 cents per share, a penny wider than the Zacks Consensus Estimate of a loss of 27 cents.

Revenues: Revenues fell short of expectations. ARIAD posted revenues of $24 million, compared to our consensus estimate of $26 million.

Key Stats: Iclusig continued to perform well in the first quarter of 2015. The company remains on track to initiate three studies on Iclusig in 2015. Meanwhile, ARIAD intends to complete patient enrolment in a phase II study on its lead pipeline candidate, brigatinib (ALK+non-small cell lung cancer), in the third quarter of 2015. Preliminary data from the study is expected in the second half of 2015 with regulatory filing slated for 2016.

Check back later for our full write up on this ARIAD earnings report later!

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ARIAD PHARMA (ARIA): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.